Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing
Resistance to multiple antiretroviral drugs among people living with HIV (PLWH) can result in a high pill burden, causing toxicity and drug interactions. Thus, the goal is to simplify treatment regimens while maintaining effectiveness. However, former resistance analysis data may not be current or c...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/7/1444 |
| _version_ | 1797587248154148864 |
|---|---|
| author | Dominic Rauschning Ira Ehren Eva Heger Elena Knops Gerd Fätkenheuer Isabelle Suárez Clara Lehmann |
| author_facet | Dominic Rauschning Ira Ehren Eva Heger Elena Knops Gerd Fätkenheuer Isabelle Suárez Clara Lehmann |
| author_sort | Dominic Rauschning |
| collection | DOAJ |
| description | Resistance to multiple antiretroviral drugs among people living with HIV (PLWH) can result in a high pill burden, causing toxicity and drug interactions. Thus, the goal is to simplify treatment regimens while maintaining effectiveness. However, former resistance analysis data may not be current or complete. The use of proviral DNA genotyping may assist in selecting appropriate treatment options. A retrospective study was carried out on individuals belonging to the Cologne HIV cohort with a resistance history to two or more antiretroviral (ARV) classes and on non-standard antiretroviral therapy (ART). Patients required former viral RNA and a recent proviral DNA resistance test to be available prior to the switch to ART. Potential discrepancies between resistance test results obtained through RNA and proviral DNA methods and the consequent virological and clinical outcomes following ART adjustments were analyzed. Out of 1250 patients, 35 were eligible for inclusion in this study. The median length of known HIV infection was 27 years, and the median duration of ART was 22 years. Of the 35 participants, 16 had received all five ARV classes. Based on proviral DNA genotyping results, ART was simplified in 17 patients. At the last follow-up examination after changing therapy, 15 patients had HIV RNA <50 copies/mL (median 202 days, range 21–636). The mean number of pills per day decreased from eight to three, and the median intake frequency decreased from two to one time/day (ranges 1–2). Our study supports the use of proviral DNA genotyping as a safe strategy for switching to simplified ART regimens. However, the lack of extensive research on the advantages of proviral DNA genotyping makes it challenging to fully assess its benefits in terms of treatment selection. |
| first_indexed | 2024-03-11T00:34:26Z |
| format | Article |
| id | doaj.art-a4e6989580094838a284adc2091f9798 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-11T00:34:26Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-a4e6989580094838a284adc2091f97982023-11-18T21:43:48ZengMDPI AGViruses1999-49152023-06-01157144410.3390/v15071444Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance TestingDominic Rauschning0Ira Ehren1Eva Heger2Elena Knops3Gerd Fätkenheuer4Isabelle Suárez5Clara Lehmann6Division of Infectious Diseases, Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, 50937 Cologne, GermanyDivision of Infectious Diseases, Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, 50937 Cologne, GermanyInstitute of Virology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Fürst-Pückler-Straße 56, 50935 Cologne, GermanyInstitute of Virology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Fürst-Pückler-Straße 56, 50935 Cologne, GermanyDivision of Infectious Diseases, Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, 50937 Cologne, GermanyDivision of Infectious Diseases, Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, 50937 Cologne, GermanyDivision of Infectious Diseases, Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, 50937 Cologne, GermanyResistance to multiple antiretroviral drugs among people living with HIV (PLWH) can result in a high pill burden, causing toxicity and drug interactions. Thus, the goal is to simplify treatment regimens while maintaining effectiveness. However, former resistance analysis data may not be current or complete. The use of proviral DNA genotyping may assist in selecting appropriate treatment options. A retrospective study was carried out on individuals belonging to the Cologne HIV cohort with a resistance history to two or more antiretroviral (ARV) classes and on non-standard antiretroviral therapy (ART). Patients required former viral RNA and a recent proviral DNA resistance test to be available prior to the switch to ART. Potential discrepancies between resistance test results obtained through RNA and proviral DNA methods and the consequent virological and clinical outcomes following ART adjustments were analyzed. Out of 1250 patients, 35 were eligible for inclusion in this study. The median length of known HIV infection was 27 years, and the median duration of ART was 22 years. Of the 35 participants, 16 had received all five ARV classes. Based on proviral DNA genotyping results, ART was simplified in 17 patients. At the last follow-up examination after changing therapy, 15 patients had HIV RNA <50 copies/mL (median 202 days, range 21–636). The mean number of pills per day decreased from eight to three, and the median intake frequency decreased from two to one time/day (ranges 1–2). Our study supports the use of proviral DNA genotyping as a safe strategy for switching to simplified ART regimens. However, the lack of extensive research on the advantages of proviral DNA genotyping makes it challenging to fully assess its benefits in terms of treatment selection.https://www.mdpi.com/1999-4915/15/7/1444HIV infectionmulti-class resistanceantiretroviral therapytherapy adjustmentdiagnostic testsresistance testing |
| spellingShingle | Dominic Rauschning Ira Ehren Eva Heger Elena Knops Gerd Fätkenheuer Isabelle Suárez Clara Lehmann Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing Viruses HIV infection multi-class resistance antiretroviral therapy therapy adjustment diagnostic tests resistance testing |
| title | Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing |
| title_full | Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing |
| title_fullStr | Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing |
| title_full_unstemmed | Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing |
| title_short | Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing |
| title_sort | optimizing antiretroviral therapy in heavily art experienced patients with multi class resistant hiv 1 using proviral dna genotypic resistance testing |
| topic | HIV infection multi-class resistance antiretroviral therapy therapy adjustment diagnostic tests resistance testing |
| url | https://www.mdpi.com/1999-4915/15/7/1444 |
| work_keys_str_mv | AT dominicrauschning optimizingantiretroviraltherapyinheavilyartexperiencedpatientswithmulticlassresistanthiv1usingproviraldnagenotypicresistancetesting AT iraehren optimizingantiretroviraltherapyinheavilyartexperiencedpatientswithmulticlassresistanthiv1usingproviraldnagenotypicresistancetesting AT evaheger optimizingantiretroviraltherapyinheavilyartexperiencedpatientswithmulticlassresistanthiv1usingproviraldnagenotypicresistancetesting AT elenaknops optimizingantiretroviraltherapyinheavilyartexperiencedpatientswithmulticlassresistanthiv1usingproviraldnagenotypicresistancetesting AT gerdfatkenheuer optimizingantiretroviraltherapyinheavilyartexperiencedpatientswithmulticlassresistanthiv1usingproviraldnagenotypicresistancetesting AT isabellesuarez optimizingantiretroviraltherapyinheavilyartexperiencedpatientswithmulticlassresistanthiv1usingproviraldnagenotypicresistancetesting AT claralehmann optimizingantiretroviraltherapyinheavilyartexperiencedpatientswithmulticlassresistanthiv1usingproviraldnagenotypicresistancetesting |